Intellia Therap

Intellia Therapeutics shares rose 5.0% intraday to $11.47 as the market repriced expectations for its lonvo-z gene-editing therapy after positive Phase 3 results in HAE showing an 87% reduction in monthly attacks, fueling optimism for a BLA filing and potential U.S. launch in H1 2027. Despite this, the stock remains 59.4% below its 52-week high of $28.25 and trades below its 20-day moving average of $14.93, though it has gained 24.5% year-to-date and bounced 44.3% from its 52-week low of $7.95. Q1 revenue fell 9.5% YoY to $15.05 million, while net loss narrowed 15.8% to $96.23 million, with EPS of -$0.81 improving 26.5% from a year earlier. However, a recent downgrade from Wolfe Research and insider stock sales have tempered sentiment, and ongoing uncertainty around commercialization timelines and competitive dynamics continues to weigh on the stock.

NTLA opened sharply lower on the US stock market, with the opening price of $12.355 tumbling over 8% from the previous close of $13.48, mainly due to a continuous decline in pre-market trading from $13.02 to $12.41 dampening sentiment. The company's Q1 2026 revenue fell 9.5% YoY to $15.048 million, with a net loss of $96.231 million narrowing 15.83% YoY, but the net profit margin remained deeply negative at -639.5%, and operating loss stood at -$100.532 million, reflecting sluggish commercialization of gene-editing therapies. The current price of $12.355 is 56.27% below the 52-week high of $28.25 and trades below the 20-day MA of $15.60 and 60-day MA of $14.22, indicating technical weakness. Though YTD gain of 34.15% and a 55.41% rebound from the 52-week low of $7.95, along with an improving ROE of -59.57%, suggest narrowing losses.

NTLA.US declined sharply intraday, driven by concerns over the commercial prospects of CRISPR gene-editing therapies and broader market sell-off. The stock opened with a gap down at $13.606, plummeted to an intraday low of $12.790, and closed at $13.015, down roughly 4.5%. The current price is 53.93% below its 52-week high of $28.25, trading below both the MA20 ($15.739) and MA60 ($14.316), indicating technical weakness. However, a slight rebound to $13.020 in post-market trading suggests some dip-buying interest.

Intellia Therapeutics fell sharply 8.3% during the regular session, as key executives sold shares after the recent rally. The CFO disposed of 4,677 shares worth ~$84,186 on July 5, following another insider sale, weighing on sentiment. This overshadowed the promising Phase 3 data for lonvo-z in hereditary angioedema, which showed an 87% reduction in monthly attacks and a planned BLA submission for a U.S. launch in H1 2027. The stock opened at $15.10, dropped to an intraday low of $14.145, and closed at $14.16, below its 20-day MA ($15.70) but marginally above the 60-day MA ($14.35). The company remains unprofitable, posting a Q1 net loss of $96.2 million on revenue of $15.0 million, though the loss narrowed 15.8% YoY. However, NTLA is still up 53.8% year-to-date, 49.9% below its 52-week high of $28.25.

Intellia Therapeutics experienced a sharp intraday decline on Tuesday, falling to a low of $15.96, down approximately 5.2% from the previous close of $16.84, reversing pre-market gains that had reached $17.37. Despite strong Phase 3 data for lonvo-z showing an 87% reduction in monthly attacks, profit-taking pressure emerged, compounded by CFO Edward J. Dulac III's recent sale of 4,677 shares worth about $84,000 and executive stock unloading. The current price of $15.98 remains 43.4% below the 52-week high of $28.25 but well above the 52-week low of $7.95, with a YTD gain of 73.5%, and is trading above both the 20-day ($15.63) and 60-day ($14.37) moving averages, indicating improved long-term momentum. However, the company remains unprofitable, with a Q1 2026 net loss of $96.2 million and a 9.5% year-over-year decline in revenue, while analysts maintain a consensus 'Hold' rating, reflecting persistent uncertainty about commercial execution.